Open Orphan PLC (AIM:ORPH, OTC:OPORF)'s (Open Orphan PLC (AIM:ORPH, OTC:OPORF)) Cathal Friel tells Proactive, Hvivo, a subsidiary has signed a $13.4m (€11.8m) contract with a US-based biotechnology company.
The deal is to test its novel antiviral candidate using the hVIVO Influenza Human Challenge Study Model.The study is expected to start in the second half of 2022 and will be conducted at hVIVO's state-of-the-art quarantine facilities in London, the company said in a statement.
It expects most of the revenues from the contract to be recognised in 2022.
